Table 1.

High level comparison of preclinical pharmacology and safety data for SGN-B6A presented in this work with those of the approved vedotin ADCs for solid tumors.

Vedotin ADC	Therapeutic dose	Number of models	Response	Tolerated dose in cynomolgus monkeys
SGN-B6A	3 mg/kg q7d × 3	1	Regression	6 mg/kg (q3w × 2)
		1	Tumor stasis
		1	Growth delay
		9 (PDX)	Regression	5 mg/kg (q7d × 4)
		7 (PDX)	Tumor stasis
		3 (PDX)	Growth delay
Tisotumab vedotin (47)	2 mg/kg single dose	1	Regression	3 mg/kg (q3w × 5)
	4 mg/kg q7d × 2	5 (PDX)	Regression
		2 (PDX)	Tumor stasis
Enfortumab vedotin (48)	4 mg/kg single dose	1	Regression	3 mg/kg (q7d × 4)
	3 mg/kg q4d × 5 or × 6	2	Regression
		2	Tumor stasis

Note: Cynomologus monkey dosing data reported in FDA review documents available to the public at www.accessdata.fda.gov.